Study on the sensitivity of primary glioma cell to chemotherapeutic agents in vitro

Abstract

Objective To study the sensitivity of primary human glioma cell to chemotherapeutic agents in vitro in order to provide an experimental basis for clinical chemotherapy of glioma. Methods The glioma cells derived from 46 cases of fresh brain glioma specimens were cultured in vitro. The sensitivity of primary cultured brain glioma cell to 4 chemotherapeutic agents which were teniposide (VM26), nimustine (ACNU), methotrexate (MTX) and temozolomide (TMZ) was determined by flow cytometry assay. Results The sensitivity sequence in 46 cases of 4 chemotherapeutic agents from high to low was VM26 (39.13%), TMZ (34.78%), ACNU (26.09%) and MTX (6.52%), there was no significant difference in the chemosensitivity in the groups of VM26, ACNU and TMZ. The chemosensitivity in MTX group was significant lower than the other groups ( χ2 = 13.883, 11.210, 6.452; P 0.05, for all). Except TMZ group, the other chemotherapeutic agents showed no significant correlation of chemosensitivity with the pathological grade of the tumor. Conclusion Glioma sensitivity to chemotherapeutic drugs in vitro is different. VM26 anti⁃glioma effect is stronger than the other 3 drugs; TMZ shows a better effect in high grade gliomas. Flow cytometry assay is a rapid drug sensitivity detecting method for screening chemotherapy drugs. DOI：10.3969/j.issn.1672-6731.2010.05.008

Keywords

• Glioma
• Antineoplastic combined chemotherapy protocols
• Drug screening assays, antitumor
• Flow cytometry